ReWalk Robotics Ltd. (NASDAQ:LFWD – Get Free Report) Director Michael Swinford bought 16,907 shares of the company’s stock in a transaction on Friday, November 22nd. The shares were purchased at an average cost of $1.83 per share, for a total transaction of $30,939.81. Following the transaction, the director now owns 43,418 shares in the company, valued at approximately $79,454.94. This represents a 63.77 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Michael Swinford also recently made the following trade(s):
- On Monday, November 25th, Michael Swinford purchased 21,622 shares of ReWalk Robotics stock. The shares were acquired at an average price of $2.03 per share, for a total transaction of $43,892.66.
- On Wednesday, November 20th, Michael Swinford acquired 16,471 shares of ReWalk Robotics stock. The stock was acquired at an average price of $1.84 per share, with a total value of $30,306.64.
ReWalk Robotics Trading Up 1.9 %
ReWalk Robotics stock opened at $2.10 on Thursday. The business’s 50 day simple moving average is $2.54 and its 200 day simple moving average is $3.49. ReWalk Robotics Ltd. has a 12 month low of $1.70 and a 12 month high of $9.10. The company has a market cap of $18.50 million, a price-to-earnings ratio of -0.84 and a beta of 2.07.
Hedge Funds Weigh In On ReWalk Robotics
An institutional investor recently bought a new position in ReWalk Robotics stock. Dimensional Fund Advisors LP acquired a new stake in ReWalk Robotics Ltd. (NASDAQ:LFWD – Free Report) in the second quarter, according to its most recent filing with the SEC. The fund acquired 13,548 shares of the company’s stock, valued at approximately $54,000. Dimensional Fund Advisors LP owned approximately 0.16% of ReWalk Robotics at the end of the most recent quarter. Institutional investors own 26.76% of the company’s stock.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of ReWalk Robotics in a research report on Wednesday, November 13th.
Check Out Our Latest Stock Report on ReWalk Robotics
About ReWalk Robotics
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Featured Stories
- Five stocks we like better than ReWalk Robotics
- ETF Screener: Uses and Step-by-Step Guide
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- How to Invest in Blue Chip Stocks
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for ReWalk Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReWalk Robotics and related companies with MarketBeat.com's FREE daily email newsletter.